<DOC>
	<DOCNO>NCT00841828</DOCNO>
	<brief_summary>Phase II randomize multicenter Trial compare Epirubicine Cyclophosphamide plus Docetaxel Trastuzumab Epirubicine Cyclophosphamide plus Docetaxel Lapatinib patient positive HER2 neu resectable breast cancer locally advance breast cancer .</brief_summary>
	<brief_title>Trastuzumab Versus Lapatinib Neoadjuvant Treatment Her2+ Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Signature write informed consent . 2 . Histological documentation breast cancer . 3 . Stage I ( T1 , N0M0 ) , IIA ( T2N0M0 ) ; IIB ( T2N1M0 , T3N0M0 ) , IIIA ( TXN2M0 ) IIIB ( T3N1M0 , T4NXM0 ) primary resectable breast cancer locally advance breast cancer . 4 . HER2positive breast cancer , define IHC 3+ positive FISH . When IHC 2+ HER2 status must assess FISH . 5 . The patient grant consent take biopsy treatment 6 . The patient grant consent send two tumor sample central laboratory molecular sub study . 7 . Two week prior randomization pregnancy test negative woman childbearing potential . 8 . Women childbearing potential must use adequate contraceptive measure participation study . Oral , injectable implant hormonal contraceptive measure permit . 9 . A WHO performance status 0 1 ( Karnofsky ³ 80 ) 10 . Age &gt; 18 year . 11 . Absence metastases disease 12 . Baseline EKG 12 week prior randomization . Baseline LVEF value within limit normal value institution &gt; 50 % basal value 13 . Normal laboratory test 2 week prior randomization Haematology value : Neutrophil count ≥ 1,5 x109/l ; Platelets ≥ 100 x 109/l ; Haemoglobine ≥ 10mg/dl Biochemistry value : serum total bilirubin £ 1 ULN ; ASAT ( SGOT ) ALAT ( SGPT ) £ 2,5 ULN ; alkaline phosphatase £ 5 ULN . The patient ASAT and/or ALAT value &gt; 1,5 ULN along alkaline phosphatase value &gt; 2,5 ULN include study . Renal function : serum creatinine £ 175 µmol/l ( 2 mg/dl ) . If value borderline , clearance creatinine must ≥ 60 ml/min 14 . 12 week prior randomization follow assessment procedure must fulfil : Bilateral mammography ; MRI Breast axillary ; Chest XRay ( PA lateral ) ; Abdominal ultrasound ; Chest CTScan ; Abdominal CTScan . Bone Scan ( applicable ) 15 . Patients must accessible treatment follow 1 . Patients lumpectomy , partial mastectomy , modify radical mastectomy allow include study . 2 . Prior Immunotherapy , hormonal therapy chemotherapy breast cancer allow . 3 . Prior therapy anthracycline taxanes ( paclitaxel docetaxel ) permit neoplasia . 4 . Prior radiotherapy breast cancer . 5 . Bilateral invasive breast carcinoma 6 . Pregnant nursing patient . Negative pregnant test ( serum urine ) 14 day prior randomization . 7 . HER 2 negative breast cancer 8 . Patients childbearing potential must use adequate contraceptive measure study treatment . No hormonal contraceptive measure permit . 9 . Any M1 breast cancer 10 . Any motor sensorial neurotoxicity grade ≥ 2 accord CTC criterion version 3 . 11 . Serious cardiac illness medical condition : Congestive heart failure , angina pectoris require specific treatment , myocardial infarction 1 year prior enroll study ; poorly control hypertension highrisk uncontrolled arrhythmias . History significative neurological psychiatric disease ( psychotic , dementia attack ) unable patient grant inform consent . Uncontrolled severe Infection Uncontrolled diabetes mellitus , active peptic ulcer 12 . Current malignancy previous malignancy breast cancer . Exception cell carcinoma skin melanoma , carcinoma situ cervix cancer past 10 year . 13 . Long term treatment corticoid except 6 month prior inclusion study low dos ( £ 20 mg metilprednisolone equivalent ) 14 . Corticoid use contraindication 15 . Concomitant hormonal replacement therapy . Previous treatment interrupt inclusion study . 16 . Cardiopathy stops patient take Docetaxel Herceptin : myocardial infarction record ; angina pectoris require specific treatment ; congestive heart failure record ; arrhythmia grade 3 4 accord CTC ver.3 ; relevant valvular disease ; chest X ray show cardiomegaly EKG show ventricular hypertrophy unless FEVI value upper URL last 3 month . 17 . Poorly control hypertension ( systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ) . The patient control hypertension treatment include study 18 . Patients treatment arrhythmia , angina congestive heart failure drug modifies cardiac conduction ( digital , beta blocker inhibitor calcium channel ) exclude . However drug take arterial tension patient include study . 19 . The patient must interrupt concomitant treatment hormonal therapy ej . raloxifen , tamoxifen selective estrogen receptor modulators ( SERM ) prior randomization . 20 . Concomitant use inhibitor inductor enzyme CYP3A4 complex ( ketoconazol , itraconazol grape juice ; rifampicin , carbamazepin fenitoin ) permit . Also , drug substrate enzyme CYP2C8 complex permit along lapatinib treatment . 21 . Concurrent treatment investigational agent participation another therapeutic clinical trial within 30 day prior randomization study . 22 . Concomitant treatment anticancer therapy 23 . Hypersensitivity reaction drug herceptin , lapatinib excipients . 24 . Male</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>